Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).

Autor: Solis-Hernandez MP; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fernandez Del Valle A; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Carmona-Bayonas A; Hematology & Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain., Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario 12 de Octubre, imas12, CNIO, UCM, CIBERONC, Madrid, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain., Benavent M; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Alonso Gordoa T; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Nuñez-Valdovino B; Medical Oncology Department, Hospital Clínico de la Universidad de Chile, Santiago de Chile, Chile., Sanchez Canovas M; Hematology & Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain., Matos I; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Alonso V; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Lopez C; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Viudez A; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain., Izquierdo M; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Calvo-Temprano D; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Grande E; Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain., Capdevila J; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. palucaji@hotmail.com.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2019 Oct; Vol. 121 (7), pp. 537-544. Date of Electronic Publication: 2019 Sep 03.
DOI: 10.1038/s41416-019-0558-7
Abstrakt: Background: The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib.
Method: A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression.
Results: One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival.
Conclusion: Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
Databáze: MEDLINE
Externí odkaz: